Zimbabwe has declined a major US health deal worth 367 million US dollars (272 million pounds) spanning five years over the United States' demand for sensitive data.
This rejection became public following a official document dated December was leaked, revealing that Head of State Emmerson Mnangagwa believed the arrangement was "skewed".
An official spokesman has since explained that the US was seeking genetic material for research and commercial purposes but refused to share the benefits from any future medical innovations.
"We must now begin the challenging and unfortunate process of ending our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had donated over $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged further talks to secure a agreement suitable to both sides so the country's critical HIV programme can continue.
Wider Context
This development follows a similar situation in neighbouring Kenya, where a high court blocked a similar deal with the US after concerns were raised about the safety of Kenyans' medical information.
After resuming the presidency recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump stated its expenditure was "inefficient" and his government was pursuing direct bilateral deals to boost openness and accountability.
As per reports, Sixteen nations in Africa have to date signed these new agreements, constituting more than $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation could have provided extraordinary benefits for Zimbabwean communities, particularly the 1.2 million presently receiving antiretroviral therapy through US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"The proposal required Zimbabwe to surrender its biological resources and data over an extended period, with no corresponding assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that shared data," his statement read.
"Put simply, our nation would provide the basic resources for medical research without any certainty that the end products would be accessible to our citizens should a future pandemic emerge."
Sovereignty and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining structures previously set up through the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to manage potential global health emergencies.
"This framework is intended to ensure that when a nation contributes its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the capability to create them."
These objections over the US deal "are not meant as anti-American sentiment," he added.
"We welcome continued dialogue with our American counterparts on how future collaboration could be arranged in a way that respects the sovereignty and dignity of both nations."
Medical Community Reaction
A leading public health body said it recognised the official position, but suggested that talks should continue since much of the country's HIV programmes were funded by external financing.
"If technical issues arise, such as those involving information security or agreement terms, these can often be resolved through technical clarification and mutually agreed protections," the group added.
The halted deal underscores the continuing challenges between accepting crucial international aid and safeguarding local interests in an increasingly data-driven world.